Gaya Herald

Glaucoma Pipeline Insight Report | 70+ Companies and 70+ Drugs | DelveInsight

 Breaking News
  • No posts were found

Glaucoma Pipeline Insight Report | 70+ Companies and 70+ Drugs | DelveInsight

January 16
18:01 2023

DelveInsight’s, “Glaucoma Pipeline Insight 2023” report provides comprehensive insights about 70+ companies and 70+ pipeline drugs in the Glaucoma pipeline landscape. It covers the Glaucoma pipeline drug profiles, including Glaucoma clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key takeaways from the Glaucoma Pipeline Report

 

  • DelveInsight’s glaucoma pipeline report depicts a robust space with 70+ active players working to develop 70+ pipeline therapies for glaucoma treatment.

 

  • The leading Glaucoma Companies are working to develop drug candidates to improve the treatment landscape including Qlaris Bio, Inc., Nicox, Allysta Pharmaceutical, ONL Therapeutics, JeniVision, Inc., Ocular Therapeutix, Laboratoires Thea, Optifye Therapeutics, PolyActiva, Laboratorios Sophia S.A de C.V., pH Pharma, Santen Pharmaceutical, Peregrine Ophthalmic, Envisia Therapeutics, Tarsier Pharma, Ocular Therapeutix, Aerpio Therapeutics, Whitecap Biosciences, LLC, Chong Kun Dang Pharmaceutical, MediPrint Ophthalmics, Inc., Noveome Biotherapeutics, Novaliq GmbH, Western Therapeutics, Sun Pharma Advanced Research Company, GrayBug inc., Biozeus, Ocuphire Pharma, VISUS THERAPEUTICS, Eyevensys, Skye Bioscience inc, Eyebiotech limited, Stuart Therapeutics, Q BioMed Inc., TALLC Inc., Mitotech, Cloudbreak Pharmaceutical, Cellix Bio, Galimedix Therapeutics, Isarna Therapeutics, Ripple Therapeutics, InMed Pharmaceuticals, Arctic Vision,  HK inno.N, Avirmax Inc., and others. 

 

  • Promising Glaucoma Pipeline Therapies in various stages of development include QLS-101, NCX 470, H-1337, CKD-351, Visomitin, D930, GAL-101, CLX-OPH-56, CBT-007, TA-A002, VT-1041, LL-BMT1, Nyxol, PDP – 716, BZ371A, MAN-01, D565, K-232, ONL1204, AGN-193408, H-1337, WB007, AKB-9778, OTX-TIC, JV-GL1, OTX-TPa, ENV515-3, ANX007, T-4032, Bimatoprost PF, BTQ 1901 / BTQ 1902, PA5108, PRO-122, PHP-201, DE-126, POLAT-001, TRS01, ST266, RTC-1119, INM-088, IN-A010,  and others.

 

  • The Glaucoma Companies and academics that are working to assess challenges and seek opportunities that could influence Glaucoma R&D. The Glaucoma pipeline therapies under development are focused on novel approaches to treat/improve the disease condition.

 

Discover recent developmental activities of Glaucoma Treatment Landscape @ Glaucoma Pipeline Outlook Report

 

Glaucoma Overview

 

Glaucoma is a group of eye diseases causing optic nerve damage. The optic nerve carries images from the retina, which is the specialized light sensing tissue, to the brain so we can see. In glaucoma, eye pressure plays a role in damaging the delicate nerve fibers of the optic nerve. When a significant number of nerve fibers are damaged, blind spots develop in the field of vision. Once nerve damage and visual loss occur, it is permanent. Most people don’t notice these blind areas until much of the optic nerve damage has already occurred. If the entire nerve is destroyed, blindness results. Glaucoma is a leading cause of blindness in the world, especially in older people. Early detection and treatment by your ophthalmologist are the keys to preventing optic nerve damage and vision loss from glaucoma.

 

Recent Developmental Activities in the Glaucoma Treatment Landscape

 

  • In August 2022, Alcon agreed to acquire Aerie Pharmaceuticals for about $770 million, betting its sprawling commercial presence can boost the uptake of the biotechnology company’s two glaucoma drugs. The Aerie Pharma acquisition brings Alcon two commercialized glaucoma products, as well as a pipeline of programs in various stages of development for other eye diseases. Alcon has been an active dealmaker, turning to M&A as a way to bolster its eye products portfolio and pipeline. Alcon will pay $15.25 for each share of Aerie, a 37% premium to the stock’s closing price.

 

  • In March 2022, Oculis S.A. and Accure Therapeutics announced a licensing agreement granting Oculis exclusive global rights to develop and commercialize ACT-01, a potentially disease-modifying therapy to protect and prevent damage to the optic nerve and retina. The agreement supports Oculis’s mission to become a global ophthalmology leader bringing breakthrough innovations to the top three segments of the market: retina, dry eye and glaucoma.

 

  • In February 2022, Ocular Therapeutix presented interim Phase I data for OTX-TIC, highlighting the product candidate’s ability to cause a clinically meaningful decrease in intraocular pressure (IOP) for six months or longer with a single implant in many subjects while preserving corneal health. The Company is actively enrolling its US-based Phase II prospective, multi-center, randomized, controlled clinical trial evaluating the safety, tolerability, and efficacy of OTX-TIC for the treatment of patients with primary open-angle glaucoma or ocular hypertension.

 

  • AM008 is a bioresorbable intracameral implant containing micronized travoprost that is injected into the anterior chamber of the eye with a target duration of drug delivery of four to six months. AM008 is in development for the reduction of elevated intraocular pressure (IOP) in patients with primary open-angle glaucoma or ocular hypertension. In a Phase I clinical trial, all cohorts experienced a mean reduction in IOP from a baseline of 7-11 mmHg with the onset of action as early as two days after insertion. Many subjects across the four cohorts demonstrated durability of activity of 6 months or longer with a single implant. Overall, no serious ocular adverse events were noted. AM008 is designed to directly address compliance issues by delivering travoprost over the course of several months with a single implant.

 

  • NCX 470 is a novel, potential best-in-class, nitric oxide (NO)-donating prostaglandin analog eye drop, designed to release bimatoprost and NO into the eye to lower intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. NCX 470 is currently in two multi-regional Phase III clinical trials. NCX 470 is covered worldwide until 2029 under a composition of matter patent with potential extension up to 5 years in the US and EU and a formulation patent until 2039 in the US, EU, Japan and China.

 

  • Sun Pharma Advanced Research Company (SPARC) reported positive top-line results from its Phase III trial (CLR_16_33) for its investigational drug, PDP-716 ophthalmic suspension, for the treatment of open angle glaucoma or ocular hypertension. The trial met its pre-specified primary endpoint, demonstrating that PDP-716 dosed once daily is equivalent to Alphagan P 0.1 percent dosed three times a day.

 

Find out more about Glaucoma Pipeline Therapies and Companies of the report @ Glaucoma Treatment Landscape

 

Glaucoma Emerging Drugs Profile

 

QLS-101: Qlaris Bio, Inc.

QLS-101 is our lead program based upon research from the laboratory of Professor Michael Fautsch at Mayo Clinic. The original compounds were first synthesized at the laboratory of Professor Peter Dosa at the University of Minnesota. QLS-101 is a novel prodrug of a well-characterized ATP-sensitive potassium (KATP) channel modulator that lowers intraocular pressure (IOP) by relaxing vessels of the vascular and vascular-like tissues distal to the Trabecular Meshwork, thereby reducing distal outflow resistance and lowering Episcleral Venous Pressure (EVP). QLS-101 has shown efficacy in lowering IOP across multiple preclinical animal species, including mice, rabbits, dogs, and non-human primates, as well as in human eye explants. To date, QLS-101 has been demonstrated to be well-tolerated with no observed hyperemia in the efficacious dose range. Qlaris Bio has initiated clinical studies with QLS-101 in patients with Primary Open Angle Glaucoma, Ocular Hypertension, Normal Tension Glaucoma, and Sturge-Weber syndrome. 

 

NCX 470: Nicox

NCX 470 is a novel, potential best-in-class, nitric oxide (NO)-donating prostaglandin analog eye drop, designed to release bimatoprost and NO into the eye to lower intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. NO is a well-known small naturally-occurring signaling molecule that plays a key role in the regulation of IOP through activation of soluble guanylate cyclase (sGC). Bimatoprost, marketed under the brand name LUMIGAN® by AbbVie, Inc., is one of the leading branded products in the class of prostaglandin analogs (PGAs). Prostaglandin analogs are the most widely used class of drugs for IOP-lowering in patients with open-angle glaucoma or ocular hypertension. Nitric oxide brings additional IOP-lowering efficacy by enhancing aqueous humor drainage from the eye via a different mechanism of action than that engaged by prostaglandin analogs. We believe a novel dual mechanism of action can achieve superior IOP-lowering compared to the parent compound alone. NCX 470 has the same mechanism-of-action as our first marketed product in the U.S. NCX 470 is currently in two multi-regional Phase 3 clinical trials, Mont Blanc and Denali, evaluating the IOP lowering efficacy of once-daily dosed NCX 470 ophthalmic solution 0.1% compared to latanoprost ophthalmic solution 0.005% in patients with open-angle glaucoma or ocular hypertension. Latanoprost, first marketed as Xalatan, is the most prescribed PGA in the U.S.

 

Glaucoma Therapeutics Assessment

There are approx. 70+ key companies which are developing the therapies for Glaucoma. The companies which have their Glaucoma drug candidates in the most advanced stage, i.e. phase III include, Nicox.

 

Learn more about the Glaucoma Clinical Trials and Drug Candidates @ Glaucoma Ongoing Clinical Trials Analysis

 

Scope of the Glaucoma Pipeline Report

  • Coverage- Global
  • Glaucoma Companies- Qlaris Bio, Inc., Nicox, Allysta Pharmaceutical, ONL Therapeutics, JeniVision, Inc., Ocular Therapeutix, Laboratoires Thea, Optifye Therapeutics, PolyActiva, Laboratorios Sophia S.A de C.V., pH Pharma, Santen Pharmaceutical, Peregrine Ophthalmic, Envisia Therapeutics, Tarsier Pharma, Ocular Therapeutix, Aerpio Therapeutics, Whitecap Biosciences, LLC, Chong Kun Dang Pharmaceutical, MediPrint Ophthalmics, Inc., Noveome Biotherapeutics, Novaliq GmbH, Western Therapeutics, Sun Pharma Advanced Research Company, GrayBug inc., Biozeus, Ocuphire Pharma, VISUS THERAPEUTICS, Eyevensys, Skye Bioscience inc, Eyebiotech limited, Stuart Therapeutics, Q BioMed Inc., TALLC Inc., Mitotech, Cloudbreak Pharmaceutical, Cellix Bio, Galimedix Therapeutics, Isarna Therapeutics, Ripple Therapeutics, InMed Pharmaceuticals, Arctic Vision,  HK inno.N, Avirmax Inc., and others.
  • Glaucoma Pipeline Therapies- QLS-101, NCX 470, H-1337, CKD-351, Visomitin, D930, GAL-101, CLX-OPH-56, CBT-007, TA-A002, VT-1041, LL-BMT1, Nyxol, PDP – 716, BZ371A, MAN-01, D565, K-232, ONL1204, AGN-193408, H-1337, WB007, AKB-9778, OTX-TIC, JV-GL1, OTX-TPa, ENV515-3, ANX007, T-4032, Bimatoprost PF, BTQ 1901 / BTQ 1902, PA5108, PRO-122, PHP-201, DE-126, POLAT-001, TRS01, ST266, RTC-1119, INM-088, IN-A010,  and others.
  • Glaucoma Segmentation: Phases, Molecule Type, Mechanism of Action, Route of Administration, Product Type

 

Table of Content

  1. Introduction
  2. Glaucoma Executive Summary
  3. Glaucoma: Overview
  4. Glaucoma Pipeline Therapeutics
  5. Glaucoma Therapeutic Assessment
  6. Glaucoma – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. NCX 470: Nicox
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. QLS-101: Qlaris Bio, Inc.
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. ONL 1204: ONL Therapeutics
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. RTC 1119: Ripple Therapeutics
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Glaucoma Key Companies
  21. Glaucoma Key Products
  22. Glaucoma- Unmet Needs
  23. Glaucoma- Market Drivers and Barriers
  24. Glaucoma- Future Perspectives and Conclusion
  25. Glaucoma Analyst Views
  26. Glaucoma Key Companies
  27. Appendix

 

For further information on the Glaucoma Drug Profiles and Future Perspectives @ Glaucoma Market Drivers and Barriers

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/